Study Results from Sun Yat-sen University Broaden Understanding of Liposomes (Abstract PO1-01-02: Final analysis of neoadjuvant chemotherapy with pegylated liposomal doxorubicin/cyclophosphamide followed by taxanes with full-course...).

A study conducted by researchers at Sun Yat-sen University in Guangzhou, China, explored the use of liposomes in neoadjuvant chemotherapy for HER2-positive breast cancer. The study involved a sequential treatment regimen with pegylated liposomal doxorubicin (PLD)/cyclophosphamide followed by taxanes and full-course trastuzumab/pertuzumab. The results showed promising anti-tumor activity and acceptable tolerability, with a high rate of pathological complete response in the breast and axilla. The study also analyzed biomarkers and found no correlation between TOP2A expression and treatment response. This research provides valuable insights into the optimal treatment approach for HER2-positive breast cancer. [Extracted from the article]